- Discussion
6
- 10.1016/s2213-8587(13)70018-4
Interlinks between sleep and metabolism
- Apr 18, 2013
- The Lancet Diabetes & Endocrinology
- Jill Jouret
Interlinks between sleep and metabolism
Circadian clocks regulate essential cellular functions and influence cancer development and treatment outcomes. Aligning therapy with circadian rhythms can improve efficacy and reduce toxicity, yet whether neuroblastoma, a heterogeneous pediatric tumor, maintains circadian function remains unclear. Here, we systematically profiled circadian dynamics across 12 neuroblastoma cell models using long-term bioluminescence assays and computational analysis. Our findings reveal heterogeneous circadian patterns ranging from robust to arrhythmic, which we linked to distinct neuroblastoma genetic features. By integrating drug sensitivity data, we identified candidate compounds whose effectiveness correlates with circadian expression profiles. Moreover, time-of-day treatment assays with the ALK inhibitor lorlatinib and frontline chemotherapeutics revealed distinct temporal drug responses that were more pronounced in circadian-competent than weakly rhythmic cell lines. Together, these findings establish circadian heterogeneity as a previously unrecognized dimension of neuroblastoma biology and highlight the therapeutic potential of chronotherapy approaches for improved treatment efficacy.
Interlinks between sleep and metabolism
Interlinks between sleep and metabolism
SUDAZFLNC – a curated and searchable online database for zebrafish lncRNAs, mRNAs, miRNAs, and circadian expression profiles
SUDAZFLNC – a curated and searchable online database for zebrafish lncRNAs, mRNAs, miRNAs, and circadian expression profiles
Read moreInferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network
Differences in individual drug responses are an obstacle to progression in cancer treatment, and predicting responses would help to plan treatment. The accumulation of cancer molecular profiling and drug response data provides opportunities and challenges to identify novel molecular signatures and mechanisms of tumor responsiveness to drugs. This study evaluated drug responses with a competing endogenous RNA (ceRNA) system that depended on competition between diverse RNA species. We identified drug response‐related ceRNA (DRCEs) by combining the sequence and expression data of long noncoding RNA (lncRNA), microRNA (miRNA), and messenger RNA (mRNA), and the survival data of cancer patients treated with drugs. We constructed a patient–drug two‐layer integrated network and used a linear weighting method to predict individual drug responses. DRCEs were found to be significantly enriched in known cancer and drug‐associated data resources, involved in biological processes known to mediate drug responses, and correlated to drug activity in cancer cell lines. The dysregulation of DRCE expression influenced drug response‐associated functions and pathways, suggesting DRCEs as potential therapeutic targets affecting drug responses. A further case study in breast invasive carcinoma (BRCA) found that DRCE expression was consistent with the drug response pattern and the aberrant expression of the two NEAT1‐related DRCEs may lead to poor response to tamoxifen therapy for patients with TP53 mutations. In summary, this study provides a framework for ceRNA‐based evaluation of clinical drug responses across multiple cancer types. Understanding the underlying molecular mechanisms of drug responses will allow improved response to chemotherapy and outcomes of cancer treatment.
Read moreZebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer
BackgroundAccurate predictions of tumor dissemination risks and medical treatment outcomes are critical to personalize therapy. Patient-derived xenograft (PDX) models in mice have demonstrated high accuracy in predicting therapeutic outcomes, but methods for predicting tumor invasiveness and early stages of vascular/lymphatic dissemination are still lacking. Here we show that a zebrafish tumor xenograft (ZTX) platform based on implantation of PDX tissue fragments recapitulate both treatment outcome and tumor invasiveness/dissemination in patients, within an assay time of only 3 days.MethodsUsing a panel of 39 non-small cell lung cancer PDX models, we developed a combined mouse-zebrafish PDX platform based on direct implantation of cryopreserved PDX tissue fragments into zebrafish embryos, without the need for pre-culturing or expansion. Clinical proof-of-principle was established by direct implantation of tumor samples from four patients.ResultsThe resulting ZTX models responded to Erlotinib and Paclitaxel, with similar potency as in mouse-PDX models and the patients themselves, and resistant tumors similarly failed to respond to these drugs in the ZTX system. Drug response was coupled to elevated expression of EGFR, Mdm2, Ptch1 and Tsc1 (Erlotinib), or Nras and Ptch1 (Paclitaxel) and reduced expression of Egfr, Erbb2 and Foxa (Paclitaxel). Importantly, ZTX models retained the invasive phenotypes of the tumors and predicted lymph node involvement of the patients with 91% sensitivity and 62% specificity, which was superior to clinically used tests. The biopsies from all four patient tested implanted successfully, and treatment outcome and dissemination were quantified for all patients in only 3 days.ConclusionsWe conclude that the ZTX platform provide a fast, accurate, and clinically relevant system for evaluation of treatment outcome and invasion/dissemination of PDX models, providing an attractive platform for combined mouse-zebrafish PDX trials and personalized medicine.
Read moreData-driven modelling approach to circadian temperature rhythm profiles in free-living conditions
The individual variation in the circadian rhythms at the physiological level is not well understood. Albeit self-reported circadian preference profiles have been consolidated, their premises are grounded on human experience, not on physiology. We used data-driven, unsupervised time series modelling to characterize distinct profiles of the circadian rhythm measured from skin surface temperature in free-living conditions. We demonstrate the existence of three distinct clusters of individuals which differed in their circadian temperature profiles. The cluster with the highest temperature amplitude and the lowest midline estimating statistic of rhythm, or rhythm-adjusted mean, had the most regular and early-timed sleep–wake rhythm, and was the least probable for those with a concurrent delayed sleep phase, or eveningness chronotype. While the clusters associated with the observed sleep and circadian preference patterns, the entirely unsupervised modelling of physiological data provides a novel basis for modelling and understanding the human circadian functions in free-living conditions.
Read moreNon-sinusoidal Waveform in Temperature-Compensated Circadian Oscillations
Non-sinusoidal Waveform in Temperature-Compensated Circadian Oscillations
Abstract 2421: Smoking, cancer treatment, and design of clinical trials.
Purpose: Smoking has been associated with poor outcomes in cancer patients, but a detailed review of the effects of smoking on cancer treatment outcomes is necessary to effectively implement structured tobacco assessments and cessation into clinical trials design. Methods: We searched Pubmed citations between 1950 and 2011 with the objective of identifying any reports relating smoking with cancer and non-cancer related outcomes in cancer patients. Our search yielded 34,000 pertinent citations of on smoking and cancer. Over 5000 of these citations appeared to include data on smoking as it might be related to cancer treatment outcomes and of these more than 800 were felt to have sufficient information to examine how smoking affects cancer treatment outcomes. Results were cataloged in tables and cross-references according to cancer disease site. Results: The vast majority of pertinent reports provide evidence showing that smoking increases the risk of cancer and non-cancer related mortality as well as treatment related adverse events. The adverse effects of smoking and treatment outcomes are observed in all major cancer disease sites (lung, head/neck, breast, gastrointestinal, gynecologic, leukemia/lymphoma, prostate, and non-prostate genitourinary). A limited number of studies examine how smoking cessation affects treatment outcomes and generally these studies show that cessation of tobacco use is associated with fewer adverse treatment outcomes. Measurement of smoking behavior is a problem due to the reliance on self-reported behavior and lack of standardization in classifying smoking status. In most studies a patients’ cigarette use is categorized into ever smoking or current/former/never smoking; however, there is a broad diversity of definitions used making it less clear exactly how smoking affects treatment outcomes. Despite methodologic issues in published reports, results demonstrate a consistent pattern that smoking increases the risk of adverse outcomes across a broad spectrum of cancer disease sites. Conclusions: This review provides evidence that smoking adversely affects cancer related and non-cancer related outcomes in patients. What is less certain is how past and/or current smoking might differentially modify treatment outcomes for patients. Clinical trials must give strong consideration for prior tobacco history, current tobacco use, and efforts to track tobacco cessation during and following cancer treatment. Citation Format: Graham W. Warren, James R. Marshall, K. Michael Cummings. Smoking, cancer treatment, and design of clinical trials. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2421. doi:10.1158/1538-7445.AM2013-2421
Read moreDifferential effects of omega-3 fatty acid docosahexaenoic acid and palmitate on the circadian transcriptional profile of clock genes in immortalized hypothalamic neurons.
Diets high in saturated fatty acids (SFAs) are associated with the development of circadian dysregulation, obesity, and Type 2 diabetes mellitus. Conversely, polyunsaturated fatty acids (PUFAs) have recently been identified to improve insulin sensitivity, reduce weight gain, and relieve obesity-induced inflammation. While saturated fatty acids, such as the prevalent dietary fatty acid palmitate, have been implicated in circadian disruption, there is a paucity of studies regarding the effects of PUFAs on circadian parameters. Therefore, the immortalized murine neuronal model, mHypoE-37, was utilized to examine the effects of the SFA palmitate and omega-3 PUFA docosahexaenoic acid (DHA) on circadian rhythms. The mHypoE-37 neurons express the core clock genes, Bmal1, Per2, and Rev-erbα, in a circadian manner. 25 μM of palmitate significantly increased the transcriptional expression of Bmal1, without altering the expression of inflammatory markers TLR4, IκBα, and IL-6, nor the orexigenic neuropeptide AgRP, suggesting that the observed disruption of the molecular clock is the result of a mechanism distinct from that of hypothalamic cellular inflammation. Furthermore, treatment with the PUFA DHA resulted in alterations in the circadian expression profile of Bmal1, although differentially from the effects of palmitate. In the presence of DHA, the disruptive effects of palmitate on Bmal1 were less pronounced, suggesting a protective effect of DHA. These studies are the first to identify the potential for omega-3 PUFAs to protect against palmitate-mediated dysregulation of circadian parameters and will ultimately improve the understanding of circadian control mechanisms.
Read moreMood Prediction of Patients With Mood Disorders by Machine Learning Using Passive Digital Phenotypes Based on the Circadian Rhythm: Prospective Observational Cohort Study.
BackgroundVirtually, all organisms on Earth have their own circadian rhythm, and humans are no exception. Circadian rhythms are associated with various human states, especially mood disorders, and disturbance of the circadian rhythm is known to be very closely related. Attempts have also been made to derive clinical implications associated with mood disorders using the vast amounts of digital log that is acquired by digital technologies develop and using computational analysis techniques.ObjectiveThis study was conducted to evaluate the mood state or episode, activity, sleep, light exposure, and heart rate during a period of about 2 years by acquiring various digital log data through wearable devices and smartphone apps as well as conventional clinical assessments. We investigated a mood prediction algorithm developed with machine learning using passive data phenotypes based on circadian rhythms.MethodsWe performed a prospective observational cohort study on 55 patients with mood disorders (major depressive disorder [MDD] and bipolar disorder type 1 [BD I] and 2 [BD II]) for 2 years. A smartphone app for self-recording daily mood scores and detecting light exposure (using the installed sensor) were provided. From daily worn activity trackers, digital log data of activity, sleep, and heart rate were collected. Passive digital phenotypes were processed into 130 features based on circadian rhythms, and a mood prediction algorithm was developed by random forest.ResultsThe mood state prediction accuracies for the next 3 days in all patients, MDD patients, BD I patients, and BD II patients were 65%, 65%, 64%, and 65% with 0.7, 0.69, 0.67, and 0.67 area under the curve (AUC) values, respectively. The accuracies of all patients for no episode (NE), depressive episode (DE), manic episode (ME), and hypomanic episode (HME) were 85.3%, 87%, 94%, and 91.2% with 0.87, 0.87, 0.958, and 0.912 AUC values, respectively. The prediction accuracy in BD II patients was distinctively balanced as high showing 82.6%, 74.4%, and 87.5% of accuracy (with generally good sensitivity and specificity) with 0.919, 0.868, and 0.949 AUC values for NE, DE, and HME, respectively.ConclusionsOn the basis of the theoretical basis of chronobiology, this study proposed a good model for future research by developing a mood prediction algorithm using machine learning by processing and reclassifying digital log data. In addition to academic value, it is expected that this study will be of practical help to improve the prognosis of patients with mood disorders by making it possible to apply actual clinical application owing to the rapid expansion of digital technology.
Read moreAnemia, hypoxia and transfusion in patients with cervix cancer: a review
Anemia, hypoxia and transfusion in patients with cervix cancer: a review
Phosphorylation of clock protein PER1 regulates its circadian degradation in normal human fibroblasts.
Recent advances suggest that the molecular components of the circadian clock generate a self-sustaining transcriptional-translational feedback loop with a period of approx. 24 h. The precise expression profiles of human clock genes and their products have not been elucidated. We cloned human clock genes, including per1, per2, per3, cry2 and clock, and evaluated their circadian mRNA expression profiles in WI-38 fibroblasts stimulated with serum. Transcripts of hPer1, hPer2, hPer3, hBMAL1 and hCry2 (where h is human) underwent circadian oscillation. Serum-stimulation also caused daily oscillations of hPER1 protein and the apparent molecular mass of hPER1 changed. Inhibitor studies indicated that the CKI (casein kinase I) family, including CKIepsilon and CKIdelta, phosphorylated hPER1 and increased the apparent molecular mass of hPER1. The inhibition of hPER1 phosphorylation by CKI-7 [ N -(2-aminoethyl)-5-chloro-isoquinoline-8-sulphonamide], a CKI inhibitor, disturbed hPER1 degradation, delayed the nuclear entry of hPER1 and allowed it to persist for longer in the nucleus. Furthermore, proteasome inhibitors specifically blocked hPER1 degradation. However leptomycin B, an inhibitor of nuclear export, did not alter the degradation state of hPER1 protein. These findings indicate that circadian hPER1 degradation through a proteasomal pathway can be regulated through phosphorylation by CKI, but not by subcellular localization.
Read moreDemographic and clinical insights into Stage IV breast cancer: a comparative approach to surgical versus non-surgical treatment outcomes
Background:Cancer is a major global health challenge, with breast cancer remaining a leading cause of mortality. Stage IV breast cancer, marked by metastasis to distant organs, is particularly complex and is often managed as incurable. Effective treatment decisions are guided by the TNM staging system, though more nuanced approaches are essential to improve patient outcomes.Methods:This retrospective observational study evaluates the demographic and clinical factors associated with Stage IV breast cancer, focusing on the impact of surgical intervention on patient outcomes. The study includes 215 Stage IV breast cancer cases, analyzing clinical variables such as age, reproductive history, hormone receptor status, lymph node involvement, and treatment modalities. Patients are categorized based on whether they received surgical or non-surgical interventions.Results:Among the study population, those who underwent surgery showed statistically significant differences in survival rates and quality of life compared to those who opted for non-surgical treatment. The analysis highlights critical factors like hormone receptor status and lymph node involvement that influence treatment outcomes, providing insights into the potential benefits of surgery even in Stage IV cases.Conclusion:This study underscores the role of surgical intervention as part of a tailored approach to managing Stage IV breast cancer. The findings contribute to a better understanding of factors influencing treatment choices and outcomes, supporting more informed decision-making in clinical practice.
Read moreAssociations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients
Associations between nutritional status, weight loss, radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients
Read moreRelationship between eating disorder duration and treatment outcome: Systematic review and meta-analysis.
This systematic review and meta-analysis examine the contribution of duration to treatment outcome for eating disorders. Studies (n = 31) were identified that examined associations (r) between duration and 45 different outcomes. We were unable to extract r for seven studies (9 outcomes) and extracted r for 36 outcomes across 24 studies (2,349 participants). Indicators of treatment outcome were heterogeneous and thus a series of different meta-analyses, aimed at increasing homogeneity, were conducted. First, we examined the average effect size for one primary eating disorder related outcome from each of the 24 studies. There was no association between duration and treatment outcome (r = .05, 95% CI: -.03:.13), with high heterogeneity. Second, we conducted three sub-group analyses to explore possible sources of heterogeneity (diagnosis: anorexia nervosa versus bulimia nervosa; nature of the outcome: binary versus continuous; or type of outcome: binary indicator of recovery, eating disorder psychopathology, weight gain). There was no significant moderation or associations between duration and outcome (ranging from .02-.08), with low to medium heterogeneity. Third, two stand-alone analyses examined outcomes related to weight gain (n = 8) and eating disorder psychopathology (n = 5), with nonsignificant rs of .23/-.06, respectively. High levels of heterogeneity were present. Duration did not influence treatment outcome across any of our meta-analyses. Increasing homogeneity and power will allow more stable estimates of the impact of duration on outcome to be calculated; to this end, future treatment studies should include outcome related to weight gain (anorexia nervosa) and improvements in eating disorder psychopathology.
Read moreAssociation between anticipated follow-up duration and treatment outcomes in anorexia nervosa: Insights from a Japanese medical prison.
Recovery rates in eating disorders generally improve with longer follow-up periods. However, the effect of a longer follow-up period itself on prognosis remains unclear due to high dropout rates. This study examined whether treatment outcomes in anorexia nervosa are influenced by the anticipated follow-up duration, using a unique cohort from a Japanese medical prison, where follow-up periods are predetermined by sentence length. Data from 149 patients diagnosed with anorexia nervosa were analyzed. Logistic and Cox regression analyses were performed to identify predictors of favorable outcomes, defined as sufficient clinical improvement to allow transfer back to the original correctional facility. Longer remaining sentence length, representing an anticipated follow-up duration, was associated with favorable outcomes (p < 0.001), independent of the actual hospitalization duration. Higher body mass index at admission and a lifetime diagnosis of an eating disorder also predicted favorable outcomes. Factors previously associated with treatment dropout, such as low educational attainment and adverse childhood experiences, were not predictive of outcomes. Longer remaining sentence length was associated with favorable treatment outcomes. Although this variable was conceptualized as a proxy for anticipated follow-up duration, physicians' expectations were not directly assessed. Therefore, the findings should be interpreted as observational and hypothesis-generating rather than causal. Future research is needed to determine whether physicians' expectations regarding anticipated follow-up duration influence treatment processes and outcomes.
Read more